Free tool
Oncology stocks
We cover 99 companies grouped under the Oncology theme. The median market value in the group is $402.61M. Across the group, the median move over the past trading day is +1.26%. 54% of the 94 with a 200-day average trade above it. Price change over the past year runs from −37.8% to +202.5% across the middle 80 percent of the group, with a median of +19.9%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
99 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| IMCR | Immunocore Holdings plc | $37.40 | +10.75% | +10.72% | +14.76% |
| DMRA | Damora Therapeutics, Inc. | $30.62 | +4.01% | +40.33% | +800.59% |
| GXE.DE | Lakefront Biotherapeutics NV | 24.68 EUR | +0.41% | −12.36% | −44.50% |
| VIR | Vir Biotechnology, Inc. | $10.71 | +21.70% | +80.30% | +144.52% |
| SNDX | Syndax Pharmaceuticals, Inc. | $19.92 | −2.92% | −6.48% | +27.20% |
| BCAX | Bicara Therapeutics Inc. | $24.58 | −11.61% | +50.06% | +117.14% |
| AAPG | Ascentage Pharma Group Internat | $16.79 | −11.12% | −36.33% | −61.38% |
| AVBP | ArriVent BioPharma, Inc. | $31.35 | +3.95% | +50.72% | +62.02% |
| REPL | Replimune Group, Inc. | $15.80 | +83.08% | +77.53% | +187.80% |
| AKTS | Aktis Oncology, Inc. | $26.69 | +10.24% | +19.15% | +19.15% |
| ORIC | ORIC Pharmaceuticals, Inc. | $13.83 | +15.06% | +69.28% | +43.76% |
| DRTS | Alpha Tau Medical Ltd. | $14.70 | +20.39% | +204.35% | +357.94% |
| IMTX | Immatics N.V. | $9.24 | +7.07% | −11.58% | +76.67% |
| GLUE | Monte Rosa Therapeutics, Inc. | $14.56 | −35.46% | −4.90% | +217.21% |
| CRVS | Corvus Pharmaceuticals, Inc. | $14.56 | +12.69% | +98.91% | +167.16% |
| 0HFQ.L | AnaptysBio, Inc. | $56.87 | −3.20% | +24.44% | +183.92% |
| 2160.T | GNI Group Ltd. | 2,765.00 JPY | +12.58% | +20.74% | +4.54% |
| PHIL.MI | Philogen S.p.A. | 23.35 EUR | −2.71% | +3.88% | +2.12% |
| CADL | Candel Therapeutics, Inc. | $13.60 | +36.55% | +150.00% | +138.18% |
| GERN | Geron Corporation | $1.55 | +4.73% | +17.42% | +9.15% |
| EUZ.DE | Eckert & Ziegler SE | 13.65 EUR | −0.29% | −9.06% | −23.06% |
| OLMA | Olema Pharmaceuticals, Inc. | $10.91 | −9.16% | −56.84% | +95.17% |
| ANL | Adlai Nortye Ltd. | $13.74 | +13.93% | +895.65% | +737.80% |
| RIGL | Rigel Pharmaceuticals, Inc. | $46.75 | +25.03% | +11.76% | +14.75% |
| AURA | Aura Biosciences, Inc. | $7.82 | +9.22% | +47.55% | +19.94% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $9.37 | +7.09% | −23.76% | −3.50% |
| MNPR | Monopar Therapeutics Inc. | $110.82 | +0.44% | +67.88% | +264.30% |
| CTMX | CytomX Therapeutics, Inc. | $3.37 | +3.69% | −20.71% | +68.50% |
| GUD.TO | Knight Therapeutics Inc. | 9.75 CAD | −0.71% | +64.97% | +49.08% |
| EIKN | Eikon Therapeutics, Inc. | $12.55 | +27.02% | −16.33% | −16.33% |
| 0QAV.L | Nanobiotix S.A. | 34.51 EUR | −2.83% | +80.19% | +346.30% |
| CU6.AX | Clarity Pharmaceuticals Ltd | 2.48 AUD | +16.98% | −33.15% | −27.91% |
| VSTM | Verastem, Inc. | $7.08 | +16.45% | −2.07% | −21.16% |
| SGMT | Sagimet Biosciences Inc. | $10.29 | +38.12% | +71.79% | +45.34% |
| CBIO | Crescent Biopharma, Inc. | $17.00 | +0.41% | +53.43% | +15.65% |
| ARVN | Arvinas, Inc. | $9.60 | +16.79% | −16.30% | +28.34% |
| DCTH | Delcath Systems, Inc. | $16.92 | +41.71% | +70.05% | +55.37% |
| 0KCS.L | OPKO Health, Inc. | $1.51 | +2.03% | +16.20% | +5.63% |
| CCCC | C4 Therapeutics, Inc. | $4.20 | +16.99% | +117.62% | +66.01% |
| TOI | Starling Oncology Inc | $6.20 | +19.46% | +68.94% | +78.67% |
| 0IL8.L | Kyntra Bio, Inc. | $7.95 | +1.50% | −11.24% | −24.41% |
| J8J.F | TransThera Sciences (Nanjing), Inc. | 1.02 EUR | −0.97% | −91.09% | −91.09% |
| RLMD | Relmada Therapeutics, Inc. | $4.59 | −11.73% | +5.03% | +635.58% |
| ALVIO.PA | Valerio Therapeutics Société anonyme | 0.79 EUR | +5.76% | +374.47% | +1150.00% |
| PBYI | Puma Biotechnology, Inc. | $9.32 | +16.65% | +61.53% | +86.77% |
| CMPX | Compass Therapeutics, Inc. | $2.53 | +21.63% | −51.06% | −16.23% |
| AVCT.L | Avacta Group Plc | 68.80 GBP | +0.44% | +19.65% | +32.31% |
| FENC | Fennec Pharmaceuticals Inc. | $11.71 | +14.69% | +52.47% | +35.38% |
| FHTX | Foghorn Therapeutics Inc. | $6.85 | +31.73% | +31.98% | +30.48% |
| PRTC.L | PureTech Health plc | 118.80 GBP | +0.51% | −4.65% | −11.34% |
| GALT | Galectin Therapeutics Inc. | $3.99 | +18.05% | −1.48% | −0.25% |
| FRX.TO | Fennec Pharmaceuticals Inc. | 15.49 CAD | +5.73% | +48.80% | +27.38% |
| AGEN | Agenus Inc. | $8.36 | +36.38% | +158.82% | +90.43% |
| CATX | Perspective Therapeutics, Inc. | $3.29 | +16.67% | +17.92% | −4.91% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $3.88 | −13.97% | +183.21% | +113.19% |
| STRO | Sutro Biopharma, Inc. | $21.44 | −10.70% | +95.62% | +155.24% |
| IMRX | Immuneering Corporation | $5.23 | +19.95% | −21.00% | −12.10% |
| BCYC | Bicycle Therapeutics plc | $4.39 | +11.14% | −34.28% | −38.34% |
| RAC.AX | Racura Oncology Ltd | 2.15 AUD | +5.39% | −25.09% | +72.00% |
| WHWK | Whitehawk Therapeutics, Inc. | $5.08 | +37.30% | +108.20% | +198.82% |
| ALXO | ALX Oncology Holdings Inc. | $2.00 | −0.99% | +73.91% | +81.82% |
| MGNX | MacroGenics, Inc. Common Stock | $4.17 | +4.25% | +159.01% | +154.27% |
| TNG.PA | Transgene SA | 0.81 EUR | +12.40% | −15.23% | −16.98% |
| GLSI | Greenwich LifeSciences, Inc. | $18.59 | +38.32% | −4.52% | +56.35% |
| 0IV3.L | Geron Corporation | $1.54 | 0.00% | +16.67% | +8.41% |
| PYXS | Pyxis Oncology, Inc. | $3.06 | +5.15% | +166.09% | +120.14% |
| IPHA | Innate Pharma S.A. | $2.27 | +28.10% | +24.73% | +1.34% |
| SPL.AX | Starpharma Holdings Limited | 0.74 AUD | −1.34% | +101.37% | +465.38% |
| ADAG | Adagene Inc. | $3.82 | +8.22% | +107.61% | +62.55% |
| IDD.DE | Innate Pharma S.A. | 1.78 EUR | +12.80% | +12.80% | −2.52% |
| IPH.PA | Innate Pharma S.A. | 1.88 EUR | +17.37% | +16.21% | +1.84% |
| TARA | Protara Therapeutics, Inc. | $3.97 | −1.73% | −26.21% | +30.16% |
| NBP | NovaBridge Biosciences | $1.93 | +8.43% | −54.80% | −59.96% |
| CHRS | Coherus Oncology, Inc. | $1.37 | −6.16% | 0.00% | +17.09% |
| BINV.ST | BioInvent International AB (publ) | 24.30 SEK | +4.07% | −17.21% | −24.30% |
| MENS | Jyong Biotech Ltd. | $2.23 | −8.23% | −34.60% | −95.26% |
| CUE | Cue Biopharma, Inc. | $26.76 | −17.84% | +164.69% | +9.05% |
| MOLN | Molecular Partners AG | $4.38 | +9.36% | +3.79% | +3.91% |
| KZIA | Kazia Therapeutics Limited | $13.79 | +12.94% | +175.80% | +83.87% |
| OKUR | OnKure Therapeutics, Inc. | $3.85 | −4.94% | +30.07% | +36.77% |
| INDP | Indaptus Therapeutics, Inc. | $1.10 | −46.32% | −60.04% | −84.51% |
| 0IMT.L | Photocure ASA | 53.80 NOK | +0.35% | −25.59% | −12.59% |
| HPHA.DE | Heidelberg Pharma AG | 2.53 EUR | −1.17% | +1.20% | −44.40% |
| SCLP.L | Scancell Holdings plc | 9.80 GBP | −1.51% | −1.01% | −6.67% |
| ADCT | ADC Therapeutics SA | $1.04 | −8.77% | −70.45% | −66.34% |
| HURA | TuHURA Biosciences, Inc. | $2.04 | −7.69% | +172.00% | −30.85% |
| 0RU5.L | Oncoinvent ASA | 70.20 NOK | −18.37% | +61.75% | +5951.72% |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | 72.40 PLN | −2.95% | −3.47% | +76.16% |
| LIXT | Nomad Power Solutions Inc | $4.15 | −6.74% | +8.07% | +26.14% |
| BDTX | Black Diamond Therapeutics, Inc. | $2.24 | +29.48% | −10.04% | −21.95% |
| ANIX | Anixa Biosciences, Inc. | $3.66 | +5.78% | +15.82% | +22.00% |
| GNLX | Genelux Corporation | $2.72 | −7.80% | −40.22% | −27.27% |
| NTHI | NeOnc Technologies Holdings, Inc. | $4.71 | +36.92% | −46.96% | −18.72% |
| 0RDB.L | Oryzon Genomics S.A. | 2.84 EUR | +0.92% | −11.03% | +4.08% |
| RVU.WA | Ryvu Therapeutics S.A. | 18.80 PLN | +25.33% | −30.76% | −34.72% |
| 4889.T | Renascience Inc. | 1,378.00 JPY | −7.70% | −3.57% | −37.68% |
| FARN.L | Faron Pharmaceuticals Oy | 41.00 GBP | −4.65% | −78.97% | −80.71% |
| ONCY | Oncolytics Biotech Inc. | $0.86 | +7.68% | −12.10% | −12.99% |
| AMAN | Amanat Acquisition Corp | $10.69 | +5.32% | +6.79% | +6.79% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.